Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia

Sponsor
FetalEase Ltd. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05913609
Collaborator
(none)
80
2
27

Study Details

Study Description

Brief Summary

Prospective, multi-center, single arm with historical control, to verify the safety and effectiveness of the Yaari Extractor used by board certified or board eligible U.S. OB/GYN physicians in the management of shoulder dystocia.

Condition or Disease Intervention/Treatment Phase
  • Device: Yaari Extractor
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
IDE Clinical Study to Evaluate the Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Yaari Extractor group

Prospective experimental arm

Device: Yaari Extractor
The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.

No Intervention: Control group

Historical control arm - retrospective review of medical records at the same study sites

Outcome Measures

Primary Outcome Measures

  1. Number of successful neonate deliveries with the Yaari Extractor device [immediately after the intervention]

    First Primary Effectiveness Endpoint

  2. Time interval (minutes) from the diagnosis of the shoulder dystocia until the neonate's delivery [immediately after the intervention]

    Second Primary Effectiveness Endpoint

  3. Maternal and neonatal adverse events [through study completion, an average of 5 days]

    Primary Safety Endpoint

Secondary Outcome Measures

  1. Ease of Use 5 point Likert scale User Questionnaire [immediately after the intervention]

    Secondary Effectiveness Endpoint

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Subject 18 years of age or older at time of consent.

  2. Subject planning on vaginal birth.

  3. Singleton pregnancy in vertex presentation.

  4. Full-term pregnancy having completed 37 weeks or more gestational weeks.

  5. Able and willing to provide written informed consent prior to enrollment.

  6. In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF).

  7. Subject with fetus experiencing shoulder dystocia as defined by ACOG Practice Bulletin 178 "Shoulder dystocia is most commonly diagnosed as failure to deliver the fetal shoulder(s) with gentle downward traction on the fetal head, requiring additional maneuvers to effect delivery."

Exclusion Criteria:
  1. Patients who have undergone ancillary standard of care maneuvers, to include first-line maneuvers (McRoberts/suprapubic pressure), prior to use of the Yaari Extractor.

  2. Cesarean section is planned for the patient.

  3. Obstetric contraindications to vaginal birth.

  4. Subject carrying fetus with known significant chromosomal or structural anomalies.

  5. Clinically estimated fetal weight ≥5kg in non-diabetic subjects.

  6. Clinically estimated fetal weight ≥4.5kg in subjects with diabetes.

  7. Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.

  8. Bleeding disorders, such as thrombocytopenia, von Willebrand's disease, bleeding disorder currently using anticoagulation medication, etc.

  9. Any maternal disease or disorder that precludes the subject from pushing effectively.

  10. If the maternal cervix is not fully dilated.

  11. If the fetal head is not completely out of the birth canal.

  12. In the presence of a non-reducible nuchal cord.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • FetalEase Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
FetalEase Ltd.
ClinicalTrials.gov Identifier:
NCT05913609
Other Study ID Numbers:
  • CLT-005
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 22, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 22, 2023